Anti-Human OX40L (Oxelumab)

Antibody Details

Product Details

Reactivity Species

Human

Host Species

Human

Expression Host

HEK-293

FC Effector Activity

Active

Immunogen

Original antibody raised against Human OX40L

Product Concentration

≥ 5.0 mg/ml

Endotoxin Level

≤ 1.0 EU/mg as determined by the LAL method

Purity

≥95% monomer by analytical SEC

Formulation

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Product Preparation

Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Pathogen Testing

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Storage and Handling

Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Regulatory Status

Research Use Only (RUO). Non-Therapeutic.

Country of Origin

USA

Shipping

Next Day 2-8°C

RRID

AB_2893898

Applications and Recommended Usage?
Quality Tested by Leinco

FC The suggested concentration for Oxelumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 μg per 10⁶ cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.

Other Applications Reported In Literature ?

FA
B

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Oxelumab. Clone R4930 binds to Human OX40L (TNFSF4). This product is for research use only.

Antigen Distribution

OX40L is expressed in various cell types including antigen presenting cells, T-cells, vascular endothelial cells, mast cells, and natural killer cells.

Background

Oxelumab is a human monoclonal antibody designed for the treatment of autoimmune diseases.³ Oxelumab recognizes human OX40L (TNFSF4). OX40L is a member of the tumor necrosis family and is the ligand for OX40 . The OX40/OX40L interaction generates an optimal T cell response and plays a significant role in determining the amount of memory T-cells remaining after the immune response.¹ Therapeutic treatments with antibodies against TNFSF can sometimes result in serious side effects.² More research is needed to understand the precise molecular mechanism of TNF inhibition. This cost-effective, research-grade Anti-Human OX40L (Oxelumab) utilizes the same variable regions from the therapeutic antibody Oxelumab making it ideal for research projects.

Antigen Details

Protein

TNFSF4

PubMed

TNFSF4

NCBI Gene Bank ID

7292

UniProt.org

Information on Uniprot.org

Research Area

Costimulatory Molecules

.

Immuno-Oncology

.

Immunology

References & Citations

1. Mahmood, T. and Yang, P. (2012) N Am J Med Sci. 4(11): 533–536

2. Spicer, P. and Runkel, L. (2019) Expert Opin Investig Drugs. 28(2):99-106

3. Heo, YS. et al. (2014) Bio Design 2(2):55-61

Technical Protocols